Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Randomized, placebo-controlled study of once-weekly exenatide in 44 non-diabetic, obese children ages 1018, which found a 2.3% decrease in BMI with exenatide compared with placebo
GO:0042110
B.StegmannB
16 Berenbaum hypothesized that the therapeutic potential of GLP-1 in OA may arise from targeting the crosstalk between macrophages and fibroblasts, which are known to drive inflammation, fibrosis, and downstream cartilage damage
Confirm injection technique delivering full dose (not leaking)
GI Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists These agents are commonly used therapies for managing diabetes and obesity, but gastrointestinal adverse effects such as nausea, vomiting, diarrhea, and constipation frequently limit therapy
US$ 28.66
US$ 29.20
US$ 21.63
US$ 21.66
US$ 28.40
US$ 28.54
